Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants
February 07 2017 - 4:10PM
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company
developing hematology and oncology therapeutics that address unmet
medical needs, today announced it has commenced an underwritten
public offering, subject to market and other conditions, to issue
and sell shares of its common stock and warrants to purchase shares
of its common stock. There can be no assurance as to whether or
when the offering may be completed, or as to the actual size or
terms of the offering.
Canaccord Genuity is acting as sole book-running manager for the
offering.
The shares of common stock and warrants to purchase shares of
common stock described above are being offered pursuant to a shelf
registration statement previously filed with and declared effective
by the Securities and Exchange Commission (SEC). A preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be filed with the SEC and will be available for free
on the SEC’s website at www.sec.gov. Copies of the preliminary
prospectus supplement and the accompanying prospectus relating to
the offering may also be obtained, when available, from Canaccord
Genuity Inc., Attention: Equity Syndicate Department, 99 High
Street, 12th Floor, Boston, Massachusetts 02110, by telephone at
(617) 371-3900, or by email at prospectus@canaccordgenuity.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of Galena’s securities. No
offer, solicitation or sale will be made in any state or other
jurisdiction in which such offering, solicitation or sale would be
unlawful.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company developing
hematology and oncology therapeutics that address unmet medical
needs. Galena’s pipeline consists of multiple mid-to-late-stage
clinical assets led by its hematology asset, GALE-401, and its
novel cancer immunotherapy programs including NeuVax™
(nelipepimut-S) and GALE-301/GALE-302. For more information, visit
www.galenabiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to,
statements about the expectations regarding the timing of the
proposed public offering. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions,
including those identified under “Risk Factors” in Galena’s Annual
Report on Form 10-K for the year ended December 31, 2015, most
recent Quarterly Reports on Form 10-Q and current reports on Form
8-K, and in the prospectus supplement to the registration statement
related to the proposed offering filed with the SEC. Actual results
may differ materially from those contemplated by these
forward-looking statements. Galena does not undertake to update any
of these forward-looking statements to reflect a change in its
views or events or circumstances that occur after the date of this
press release.
NeuVax is a trademark of Galena Biopharma, Inc.
Source: Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
ir@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024